Elsevier is the New Publisher of Value in Health, the Official Journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)By Elsevier, PRNE
Tuesday, January 4, 2011
OXFORD, England, January 5, 2011 - Elsevier, the world's leading publisher of scientific, technical and
medical information, announced today that it has become the new publisher of
the International Society for Pharmacoeconomics and Outcomes Research's
(ISPOR) journal Value in Health.
Value in Health (
n#description) is a multidisciplinary peer-reviewed journal reporting on
outcomes research evaluations of medical technologies including
pharmaceuticals, biologics, devices, medical procedures, and other health
care interventions. The journal is published eight times a year.
The Journal provides a scientific forum for communicating clinical,
economic, and patient-reported outcomes research methods and findings,
furthering ISPOR's mission that 'society allocates scarce health care
resources wisely, fairly, and efficiently. Value in Health is also a sounding
board for the discussion of health policy issues related to health economics
and outcomes research studies associated with all medical technologies.
Topics include budget impact/cost-effectiveness/cost-utility/cost-benefit
analysis, health utilities/preferences, patient-reported
outcomes/health-related quality of life/health status research, health
technology assessment, disease management, with study designs (prospective,
retrospective, observational and clinical trials, and modeling), and critical
reviews of existing literature.
ISPOR (www.ispor.org/) is a (not-for-profit) member driven,
international, educational and scientific organization promoting the science
of pharmacoeconomics and outcomes research (clinical, economic, and
patient-reported outcomes) and the translation of outcomes research into
health care decisions. ISPOR has over 5,500 active members from 86 countries
and 3,300 members in its 42 regional chapters totaling over 8,900 members.
ISPOR represents researchers and practitioners including pharmacists,
physicians, economists, public health and other professionals involved in
pharmacoeconomic analysis and health outcomes assessment as well as users of
this information in health care decisions in government, hospitals, managed
care, and pharmacy benefit design organizations.
Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com/) and Cell
(www.cell.com/), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (www.sciencedirect.com/), SciVerse Scopus
(www.scopus.com/), Reaxys (https://www.reaxys.com/), MD
Consult (www.mdconsult.com/) and Nursing
Consult (www.nursingconsult.com/), which
enhance the productivity of science and health professionals, and the SciVal
suite (www.scival.com/) and MEDai's Pinpoint Review (
www.medai.com/), which help research and health care institutions
deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com/) employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC (
www.reedelsevier.com/), a world-leading publisher and
information provider, which is jointly owned by Reed Elsevier PLC and Reed
Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).
(Due to the length of some of the URLs, it may be necessary to copy and
paste the hyperlink into your Internet browser's URL address field. Remove
the space if one exists.)
Media Contact Mustak Kothia firstname.lastname@example.org +44(0)20-7424-4404
Media Contact: Mustak Kothia, m.kothia at elsevier.com, +44(0)20-7424-4404
Tags: Elsevier, England, January 5, Oxford, United Kingdom